Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low?

X4 Pharmaceuticals Inc XFOR shares are trading lower despite releasing what it described as positive phase 2 data for mavorixafor for WHIM syndrome, a rare congenital immune deficiency.

  • In a poster presentation at the American Society of Hematology Annual Meeting, treatment with mavorixafor led to increases in neutrophils, lymphocytes, and monocytes and sustained improvements in infections and warts ongoing Phase 2 open-label extension trial.
  • Infection rates also decreased as the mavorixafor dose increased.
  • Top-line data from a 52-week phase 3 trial is expected in Q4 2022.
  • In a separate poster, the Company posted new efficacy and safety data from the ongoing Phase 1b trial of mavorixafor + ibrutinib for Waldenström's macroglobulinemia (WM).
  • A 100% overall response rate was observed for the combination treatment in frontline and refractory patients.
  • Study enrollment ongoing at the highest dose of mavorixafor; longer-term response data, dose selection, and regulatory updates expected in 2022.
  • Price Action: XFOR shares are down 34.6% at $2.51 during the market session on the last check Monday.
  • Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralASH21Briefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!